- Home
- SGP vs MFA Comparison
SGP vs MFA Comparison
Compare SGP & MFA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SGP | MFA |
|---|---|---|
| Founded | 2019 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 932.9M | 1.0B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | SGP | MFA |
|---|---|---|
| Price | $23.46 | $9.35 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 6 |
| Target Price | ★ $45.00 | $11.05 |
| AVG Volume (30 Days) | 49.1K | ★ 1.4M |
| Earning Date | 05-15-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 14.16% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $10.02 |
| P/E Ratio | ★ N/A | $7.75 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $20.15 | $8.78 |
| 52 Week High | $30.56 | $10.57 |
Technical Indicators
Market Signals| Indicator | SGP | MFA |
|---|---|---|
| Relative Strength Index (RSI) | 44.29 | 36.37 |
| Support Level | $20.95 | $8.88 |
| Resistance Level | $26.29 | $10.26 |
| Average True Range (ATR) | 1.47 | 0.22 |
| MACD | 0.00 | -0.08 |
| Stochastic Oscillator | 38.44 | 1.36 |
Price Performance
Historical ComparisonAbout SGP SpyGlass Pharma Inc. Common Stock
SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company is developing two programs: the BIM-IOL System, which is intended for use during cataract surgery to deliver glaucoma treatment, and the BIM-DRS, which is designed for glaucoma patients who are not undergoing cataract surgery.
About MFA MFA Financial Inc.
MFA Financial Inc is a specialty finance company that invests in and finances residential mortgage assets. Its principal business objective is to deliver shareholder value through the generation of distributable income and through asset performance linked to residential mortgage credit fundamentals. The company selectively invests in residential mortgage assets with a focus on credit analysis, projected prepayment rates, interest rate sensitivity and expected return. The company's reportable segments include mortgage-related assets and Lima One.